89BIO (ETNB) Competitors $9.19 +0.16 (+1.77%) Closing price 04:00 PM EasternExtended Trading$9.22 +0.04 (+0.38%) As of 06:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ETNB vs. NUVL, MRUS, CRSP, TGTX, CYTK, AAPG, KRYS, ACAD, ADMA, and TLXShould you be buying 89BIO stock or one of its competitors? The main competitors of 89BIO include Nuvalent (NUVL), Merus (MRUS), CRISPR Therapeutics (CRSP), TG Therapeutics (TGTX), Cytokinetics (CYTK), Ascentage Pharma Group International (AAPG), Krystal Biotech (KRYS), ACADIA Pharmaceuticals (ACAD), ADMA Biologics (ADMA), and Telix Pharmaceuticals (TLX). These companies are all part of the "pharmaceutical products" industry. 89BIO vs. Its Competitors Nuvalent Merus CRISPR Therapeutics TG Therapeutics Cytokinetics Ascentage Pharma Group International Krystal Biotech ACADIA Pharmaceuticals ADMA Biologics Telix Pharmaceuticals Nuvalent (NASDAQ:NUVL) and 89BIO (NASDAQ:ETNB) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment and earnings. Do insiders & institutionals believe in NUVL or ETNB? 97.3% of Nuvalent shares are owned by institutional investors. 10.2% of Nuvalent shares are owned by insiders. Comparatively, 2.8% of 89BIO shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more risk & volatility, NUVL or ETNB? Nuvalent has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500. Comparatively, 89BIO has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500. Which has higher earnings and valuation, NUVL or ETNB? Nuvalent is trading at a lower price-to-earnings ratio than 89BIO, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvalentN/AN/A-$260.76M-$4.90-15.6989BION/AN/A-$367.08M-$3.61-2.55 Is NUVL or ETNB more profitable? Nuvalent's return on equity of -32.58% beat 89BIO's return on equity.Company Net Margins Return on Equity Return on Assets NuvalentN/A -32.58% -30.14% 89BIO N/A -94.48%-80.92% Does the media favor NUVL or ETNB? In the previous week, Nuvalent and Nuvalent both had 14 articles in the media. Nuvalent's average media sentiment score of 1.52 beat 89BIO's score of 1.05 indicating that Nuvalent is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvalent 11 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Very Positive 89BIO 9 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer NUVL or ETNB? Nuvalent currently has a consensus target price of $120.80, indicating a potential upside of 57.09%. 89BIO has a consensus target price of $26.63, indicating a potential upside of 189.72%. Given 89BIO's higher probable upside, analysts plainly believe 89BIO is more favorable than Nuvalent.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvalent 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.0989BIO 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.00 SummaryNuvalent beats 89BIO on 9 of the 12 factors compared between the two stocks. Get 89BIO News Delivered to You Automatically Sign up to receive the latest news and ratings for ETNB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ETNB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ETNB vs. The Competition Export to ExcelMetric89BIOMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.34B$3.10B$5.69B$9.68BDividend YieldN/A2.28%6.66%4.54%P/E RatioN/A20.9982.6526.40Price / SalesN/A207.75454.15178.36Price / CashN/A43.5325.7028.92Price / Book2.619.8811.246.06Net Income-$367.08M-$53.38M$3.28B$266.05M7 Day Performance-1.82%-0.14%0.15%-0.07%1 Month Performance0.33%9.18%8.34%5.83%1 Year Performance-3.26%7.53%54.21%17.88% 89BIO Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ETNB89BIO2.465 of 5 stars$9.19+1.8%$26.63+189.7%-4.9%$1.34BN/A0.0040News CoveragePositive NewsAnalyst ForecastNUVLNuvalent3.2052 of 5 stars$74.05-2.7%$118.91+60.6%-10.0%$5.49BN/A0.0040News CoveragePositive NewsMRUSMerus2.7392 of 5 stars$65.74-2.6%$88.64+34.8%+29.1%$5.10B$36.13M0.0037Positive NewsCRSPCRISPR Therapeutics3.4485 of 5 stars$54.13-0.3%$71.60+32.3%+8.6%$4.94B$37.31M0.00460Positive NewsAnalyst RevisionTGTXTG Therapeutics4.552 of 5 stars$28.53-3.1%$46.25+62.1%+24.9%$4.67B$329M77.11290Positive NewsCYTKCytokinetics4.1063 of 5 stars$37.01-3.5%$71.58+93.4%-38.1%$4.59B$18.47M-7.26250Trending NewsAnalyst ForecastInsider TradeOptions VolumeGap UpAAPGAscentage Pharma Group InternationalN/A$43.48-9.2%N/AN/A$4.45B$134.35M0.00600Gap DownHigh Trading VolumeKRYSKrystal Biotech4.7558 of 5 stars$146.77-2.5%$210.38+43.3%-24.3%$4.36B$290.52M30.59210Positive NewsACADACADIA Pharmaceuticals3.9994 of 5 stars$25.32-1.6%$28.88+14.0%+56.8%$4.34B$957.80M19.04510News CoverageAnalyst RevisionADMAADMA Biologics3.9904 of 5 stars$17.01-4.4%$27.67+62.6%-0.3%$4.25B$426.45M19.78530Positive NewsTLXTelix PharmaceuticalsN/A$12.20-2.2%$22.33+83.1%N/A$4.22B$516.72M0.00N/AAnalyst Revision Related Companies and Tools Related Companies Nuvalent Alternatives Merus Alternatives CRISPR Therapeutics Alternatives TG Therapeutics Alternatives Cytokinetics Alternatives Ascentage Pharma Group International Alternatives Krystal Biotech Alternatives ACADIA Pharmaceuticals Alternatives ADMA Biologics Alternatives Telix Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ETNB) was last updated on 9/2/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored“Shadow Group” in Washington, DC Could Crash MarketNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 89BIO Please log in to your account or sign up in order to add this asset to your watchlist. Share 89BIO With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ETNB Stock Alerts